Spring direct naar de hoofdnavigatie of de inhoud
‘To explore, together with a client, how the best IP protection can be obtained is for me the logical next step after an invention has been made.’
Home / Experts / Frits Michiels
Frits Michiels

Frits Michiels

  • Life Sciences
  • European and Dutch Patent Attorney
  • Valuation specialist
  • Partner
T +31 70 416 67 30

Frits Michiels has had an extensive scientific career in both knowledge institutes and biotech companies. From 2004, he was employed as IP manager at Galapagos Genomics BV and subsequently also at other Dutch biotech startups, such as Agendia and Merus. He has worked for V.O. since 2006.

Continue reading

He is specialized in biochemistry, molecular biology, cell biology, diagnostics, signal transduction, and medical biotechnology. His clients are primarily knowledge institutes and start ups. He is involved in patent prosecution and strategic advice.

Working experience

  • Patent Attorney, V.O. (2006-present)
  • Merus (2006)
  • Galapagos Genomics (1999-2005)
  • Senior Scientist at the Netherlands Cancer Institute (1994-1998)
  • Post-Doc, Amsterdam Medical Center (1991-1993)
  • PhD research at Max Planck Institute for Biochemistry, Munich (1985-1990)

Education

  • PhD in Genetics, Radboud University Nijmegen (1990)
  • MSc in Microbiology, Radboud University Nijmegen (1984)

Publications

  • Michiels, GAM Damages extended to after termination of a tort. MIP Vol 205: 94-95 (2011)
  • JP ten Klooster, EE Evers, L Janssen, LM Machesky, F Michiels, P Hordijk and JG Collard. Biochem J. 397, 39–45 (2006)
  • GJ Arts, E Langemeijer, R Tissingh, L Ma, H Pavliska, K Dokic, R Dooijes, E Mesić, R Clasen, F Michiels, J van der Schueren, M Lambrecht, S Herman, R Brys, K Thys, M Hoffmann, P Tomme, H van Es. Genome Res 13, 2325-32 (2003)
  • A Malliri, RA van der Kammen, K Clark, M van der Valk, F Michiels & JG Collard. Nature 417, 867-871 (2002)
  • F Michiels et al. Nature Biotech 20, 1154-1157 (2002)
  • R Engers, E Springer, F Michiels, JG Collard, HE Gabbert. J Biol Chem 276, 41889-97 (2001)
  • WO2002057463 Swap/counter selection; a rapid cloning
  • WO2002070744 Adenoviral library assay for E2F regulatory genes and methods and compositions for screening compounds method
  • WO2005124342 Methods and means for treatment of osteoarthritis

Languages

  • English
  • Dutch
  • German

See also

Also see these experts

Sara Calitz

Sara Calitz

  • European Patent Attorney
  • Associate
+31 30 785 63 60
Tamara Elmore

Tamara Elmore

  • European and Dutch Patent Attorney, European Patent Litigator
  • United States Patent Agent
  • Partner
+31 30 785 63 64
More experts

News

The license of right for the unitary patent: smart cost saving or strategic limitation?

With the introduction of the European patent with unitary effect (unitary patent or UP), patent holders now have access to new strategic tools. One of these is the license of right (LoR). What does such a declaration entail, and what advantages and disadvantages can it have for the protection of your intellectual property?Continue reading

UPC jurisdiction over UK designations and conditional infringement relief in Fujifilm v Kodak

In the case of Kodak vs. Fujifilm concerning EP 3 511 174 on 2 June 2026 before the Court of Appeal of the Unified Patent, the Court of Appeal addressed the UPC’s jurisdiction over the UK designation of a European patent. The decision is important because it applies the CJEU’s reasoning in BSH v Electrolux […]Continue reading

Case Law Clarity

Visitors to the V.O. website may already have noticed that it has recently been expanded with a new section: Case Law Clarity. With this addition, the website responds to the growing need for clear and consistent explanations of complex legal developments in patent law.Continue reading

More news